The Patent Finder

Seragen, Inc.

Also on record
Records under this name other than patents Seragen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Seragen, Inc.

PatentTitleStatus Expires Confidence
US 6,992,108Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
Formerly held
Term ended
Term ended Jan 31, 2023 · From the USPTO record
Term endedTerm ended Jan 31, 2023From the USPTO record
US 6,316,404Treating NIDDM with RXR agonists
Formerly held
Term ended
Term ended Dec 22, 2020 · From the USPTO record
Term endedTerm ended Dec 22, 2020From the USPTO record
US 6,228,862Treating NIDDM with RXR agonists
Formerly held
Term ended
Term ended May 11, 2019 · From the USPTO record
Term endedTerm ended May 11, 2019From the USPTO record
US 6,320,074Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
Formerly held
Term ended
Term ended Oct 27, 2018 · From the USPTO record
Term endedTerm ended Oct 27, 2018From the USPTO record
US 6,521,633Treating NIDDM with RXR agonists
Formerly held
Term ended
Term ended Feb 20, 2018 · From the USPTO record
Term endedTerm ended Feb 20, 2018From the USPTO record
US 7,655,699Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
Formerly held
Lapsed on the fee record
Ended Feb 2, 2018 · From the USPTO record
Lapsed on the fee recordEnded Feb 2, 2018From the USPTO record
US 6,074,636Method of using cell surface receptor targeted molecules for the treatment of viral diseases
Formerly held
Term ended
Term ended Jun 13, 2017 · From the USPTO record
Term endedTerm ended Jun 13, 2017From the USPTO record
US 6,043,279Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
Formerly held
Term ended
Term ended Feb 12, 2017 · From the USPTO record
Term endedTerm ended Feb 12, 2017From the USPTO record
US 6,022,950Hybrid molecules having translocation region and cell-binding region
Term ended
Term ended Feb 8, 2017 · From the USPTO record
Term endedTerm ended Feb 8, 2017From the USPTO record
US 6,028,052Treating NIDDM with RXR agonists
Formerly held
Term ended
Term ended Sep 17, 2016 · From the USPTO record
Term endedTerm ended Sep 17, 2016From the USPTO record
10 of 29 patents shown.
Pro members see all 29.
Pro members: see all 29 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited